Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1
- 29 September 2023
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 21 (1) , 29-39
Abstract
Neurofibromatosis type 1 is a genetic syndrome characterized by a wide variety of tumor and non-tumor manifestations. Bone-related issues, such as scoliosis, tibial dysplasia, and low bone mineral density, are a significant source of morbidity for this population with limited treatment options. Some of the challenges to developing such treatments include the lack of consensus regarding the optimal methods to assess bone health in neurofibromatosis type 1 and limited data regarding the natural history of these manifestations. In this review, the Functional Committee of the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration: (1) presents the available techniques for measuring overall bone health and metabolism in persons with neurofibromatosis type 1, (2) reviews data for use of each of these measures in the neurofibromatosis type 1 population, and (3) describes the strengths and limitations for each method as they might be used in clinical trials targeting neurofibromatosis type 1 bone manifestations. The Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration supports the development of a prospective, longitudinal natural history study focusing on the bone-related manifestations and relevant biomarkers of neurofibromatosis type 1. In addition, we suggest that the neurofibromatosis type 1 research community consider adding the less burdensome measurements of bone health as exploratory endpoints in ongoing or planned clinical trials for other neurofibromatosis type 1 manifestations to expand knowledge in the field.Keywords
This publication has 79 references indexed in Scilit:
- Multiple increased osteoclast functions in individuals with neurofibromatosis type 1American Journal of Medical Genetics Part A, 2011
- Radiation exposure in X-ray-based imaging techniques used in osteoporosisEuropean Radiology, 2010
- Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2010
- Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomographyBone, 2009
- Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1Brain and Development, 2008
- Evidence of Increased Bone Resorption in Neurofibromatosis Type 1 Using Urinary Pyridinium Crosslink AnalysisPediatric Research, 2008
- Generalized metabolic bone disease in Neurofibromatosis type IMolecular Genetics and Metabolism, 2008
- Bone Mineral Density in Children and Adolescents with Neurofibromatosis Type 1The Journal of Pediatrics, 2007
- Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1–haploinsufficient osteoclast functionsJournal of Clinical Investigation, 2006
- Overdiagnosis of osteoporosis in children due to misinterpretation of Dual-energy x-ray absorptiometry (DEXA)The Journal of Pediatrics, 2004